Stay updated on Anamorelin HCl in NSCLC-C: Clinical Trial
Sign up to get notified when there's something new on the Anamorelin HCl in NSCLC-C: Clinical Trial page.

Latest updates to the Anamorelin HCl in NSCLC-C: Clinical Trial page
- Check6 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe ROMANA 3 study page now shows a 403 error and the detailed study content has been removed, leaving only navigation and footer information.SummaryDifference15%

- Check34 days agoChange DetectedThe study locations in Israel were updated. Qiryat Krinitzi was removed and Tel Litwinsky was added.SummaryDifference0.0%

- Check41 days agoChange DetectedA new study site, Qiry Krinitzi, Israel, has been added to the locations list, and Tel Litwinsky, Israel has been removed; this updates the geographic options for enrollment and site coverage.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page shows a new revision label Revision: v3.6.6, replacing Revision: v3.6.5, indicating a minor update to the document revision history.SummaryDifference0.0%

- Check69 days agoChange DetectedAn error page HTML is now shown in place of the ROMANA 3 study record content, so the page displays an 'An error occurred' message rather than the trial details. This indicates the record is currently unavailable and unable to present study information.SummaryDifference14%

Stay in the know with updates to Anamorelin HCl in NSCLC-C: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anamorelin HCl in NSCLC-C: Clinical Trial page.